Virtus ETF Advisers’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-241
Closed -$1K 442
2020
Q2
$1K Hold
241
﹤0.01% 442
2020
Q1
$1K Hold
241
﹤0.01% 410
2019
Q4
$1K Buy
+241
New +$627 ﹤0.01% 451

Other funds holding BMY.RT

Virtus ETF Advisers's BMY.RT Position: Q3 2020 in Review

Virtus ETF Advisers sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 241 shares — an estimated $1K sold.

Virtus ETF Advisers first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $1K in Q2 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Virtus ETF Advisers reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Virtus ETF Advisers sold 241 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $1K.
  • Virtus ETF Advisers first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • Virtus ETF Advisers's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1K in Q2 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Virtus ETF Advisers's 13F filing for Q3 2020, filed 13 Nov 2020.